$0.92
2.63% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US00972G1085
Symbol
AKTX

Akari Therapeutics Plc Sponsored ADR Stock price

$0.93
-0.21 18.50% 1M
-0.05 4.64% 6M
-0.30 24.18% YTD
-2.67 74.23% 1Y
-25.08 96.44% 3Y
-34.08 97.36% 5Y
-579.08 99.84% 10Y
-3,999.08 99.98% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
-0.02 2.62%
ISIN
US00972G1085
Symbol
AKTX
Industry

Key metrics

Basic
Market capitalization
$31.0m
Enterprise Value
$29.8m
Net debt
positive
Cash
$2.7m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 7.2
EV/Sales
- | 7.0
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
44.0%
Return on Equity
-89.0%
ROCE
-37.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $4.3m
EBITDA
$-12.8m | -
EBIT
$-12.8m | $-15.5m
Net Income
$-12.3m | -
Free Cash Flow
$-9.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
54.9% | -
EBIT
54.9% | 6.6%
Net Income
47.0% | -
Free Cash Flow
42.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
0.2%
Employees
9
Rev per Employee
$0.0
Show more

Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Akari Therapeutics Plc Sponsored ADR forecast:

Buy
88%
Hold
13%

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.92 9.92
43% 43%
-
- Research and Development Expense 2.87 2.87
74% 74%
-
-13 -13
55% 55%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
55% 55%
-
Net Profit -12 -12
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
8 days ago
BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the pres...
Neutral
GlobeNewsWire
24 days ago
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1 Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari's commitment to continued research to better understand the multiple effects of its novel spliceosome modulator, PH1
Neutral
GlobeNewsWire
30 days ago
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body
More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Abizer Gaslightwala
Employees 9
Founded 2004
Website www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today